Huangming Hong

Huangming Hong


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2024 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
ZHZongyao Huang
Zongyao Huang
YFYao Fu
Yao Fu
HYHong Yang
Hong Yang
YZYehan Zhou
Yehan Zhou
MSMin Shi
Min Shi
YLYang Liu
Yang Liu
T-cell lymphoma is a highly invasive tumor with significant heterogeneity. Invasive tissue biopsy is the gold standard for acquiring molecular data and categorizing lymphoma patients into genetic subtypes. However, surgical intervention is unfeasible for patients who are critically ill, have unresectable tumors, or demonstrate low compliance, making tissue biopsies inaccessible to these patients. A critical need for a minimally invasive approach in T-cell lymphoma is evident, particularly in the areas of early diagnosis, prognostic monitoring, treatment response, and drug resistance. Therefore, the clinical application of liquid biopsy techniques has gained significant attention in T-cell lymphoma. Moreover, liquid biopsy requires fewer samples, exhibits good reproducibility, and enables real-time monitoring at molecular levels, thereby facilitating personalized health care. In this review, we provide a comprehensive overview of the current liquid biopsy biomarkers used for T-cell lymphoma, focusing on circulating cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), Epstein-Barr virus (EBV) DNA, antibodies, and cytokines. Additionally, we discuss their clinical application, detection methodologies, ongoing clinical trials, and the challenges faced in the field of liquid biopsy.

5 July 2022 in American Journal of Hematology
Verified
Journal Article
Open access
JLJing Quan Lim
Jing Quan Lim
DHDachuan Huang
Dachuan Huang
JCJason Yongsheng Chan
Jason Yongsheng Chan
YLYurike Laurensia
Yurike Laurensia
EWEsther Kam Yin Wong
Esther Kam Yin Wong
COChoon Kiat Ong
Choon Kiat Ong
With lowering costs of sequencing and genetic profiling techniques, genetic drivers can now be detected readily in tumors but current prognostic models for Natural‐killer/T cell lymphoma (NKTCL) have yet to fully leverage on them for prognosticating patients. Here, we used next‐generation sequencing to sequence 260 NKTCL tumors, and trained a genomic prognostic model (GPM) with the genomic mutations and survival data from this retrospective cohort of patients using LASSO Cox regression. The GPM is defined by the mutational status of 13 prognostic genes and is weakly correlated with the risk‐features in International Prognostic Index (IPI), Prognostic Index for Natural‐Killer cell lymphoma (PINK), and PINK‐Epstein–Barr virus (PINK‐E). Cox‐proportional hazard multivariate regression also showed that the new GPM is independent and significant for both progression‐free survival (PFS, HR: 3.73, 95% CI 2.07–6.73; p < .001) and overall survival (OS, HR: 5.23, 95% CI 2.57–10.65; p = .001) with known risk‐features of these indices. When we assign an additional risk‐score to samples, which are mutant for the GPM, the Harrell's C‐indices of GPM‐augmented IPI, PINK, and PINK‐E improved significantly (p < .001, χ2 test) for both PFS and OS. Thus, we report on how genomic mutational information could steer toward better prognostication of NKTCL patients.

27 February 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
HHHuangming Hong
Huangming Hong
XFXiaojie Fang
Xiaojie Fang
HHHe Huang
He Huang
ZWZhao Wang
Zhao Wang
TLTongyu Lin
Tongyu Lin
HYHerui Yao
Herui Yao

20 February 2024 in Leukemia
Verified
Journal Article
Closed access
PDF file
ZCZegeng Chen
Zegeng Chen
HHHe Huang
He Huang
HHHuageng Huang
Huageng Huang
LYLe Yu
Le Yu
HWHuawei Weng
Huawei Weng
Tongyu LinTongyu Lin
Tongyu Lin

28 January 2019 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
HHHuangming Hong
Huangming Hong
HHHe Huang
He Huang
XFXiaojie Fang
Xiaojie Fang
ZWZhao Wang
Zhao Wang
SYSheng Ye
Sheng Ye
Tongyu LinTongyu Lin
Tongyu Lin

1 June 2020 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
NXNing Xie
Ning Xie
TQTao Qin
Tao Qin
WRWei Ren
Wei Ren
HYHerui Yao
Herui Yao
YYYunfang Yu
Yunfang Yu
HHHuangming Hong
Huangming Hong
Purpose: To assess the efficacy and safety of cyclin-dependent kinases 4 and 6 inhibitors (CDKi) combined with endocrine therapy (ET) in women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) and compare the efficacy of different CDKi (palbociclib, ribociclib, or abemaciclib). Materials and Methods: This study based on randomized Phase 2 or 3 trials of CDKi plus ET compared with placebo plus ET for women with HR+/HER2−ABC and identify relevant randomized clinical trials (RCTs) published prior to February 2020. The primary endpoint was progression-free survival (PFS), the secondary endpoints included overall survival (OS), objective response rate (ORR), clinical benefit response (CBR) and safety. The PROSPERO registry number is 42018081105. Results: The results from eight trials including 4580 participants were pooled. Evidence indicated that the PFS of CDKi group was significantly prolonged (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.50– 0.60, P < 0.01) compared with placebo group. The ORR and CBR were better (risk ratio [RR] 1.47, 95% CI 1.30– 1.67, P < 0.01; 1.24, 95% CI 1.15– 1.35, P < 0.01) in the CDKi group. The OS of CDKi group (HR 0.75, 95% CI 0.67– 0.85, P < 0.01) was significantly longer than ET alone. Subgroup analyses confirmed that the benefit was consistent across most subgroups. Subgroup analyses showed no statistically significant difference of PFS among three CDKi: palbociclib vs ribociclib (HR 0.55, 95% CI 0.49– 0.60, P = 0.34), palbociclib vs abemaciclib (HR 0.53, 95% CI, 0.47– 0.59, P = 0.61), and ribociclib vs abemaciclib (HR 0.56, 95% CI, 0.51– 0.62, P = 0.72). Treatment-related grade 3 or 4 hematologic adverse events (AEs) were more frequently in CDKi group. Conclusion: CDKi combined with ET can significantly prolong PFS and improve the ORR, CBR and OS in patients with HR+/HER2− ABC. However, the advantage of different CDKi has not been established.